ClinicalTrials.gg
CompletedNCT05383209Updated Aug 15, 2025Results posted

Study of EYP-1901 in Patients With Nonproliferative Diabetic Retinopathy (NPDR)

A Phase 2 interventional study of EYP-1901 and Sham IVT in Nonproliferative Diabetic Retinopathy, sponsored by EyePoint Pharmaceuticals, Inc.. Completed at 36 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-15.

Sponsored by EyePoint Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
77
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 267 studies in Diabetic Retinopathy with a site in United States — 36 open to participants now, 55 under way, 6 of them phase 3. Diabetic Retinopathy · United States.

Enrollment
96th of 196
77 · median 72
Started
2022
with 17 others
Phase 2
52 of 267
3 open now
Registered
204th of 267
by date

Among the 267 studies in Diabetic Retinopathy with a site in United States, this one is the 96th largest by enrollment of the 196 interventional ones that give a count, is one of 18 that started in 2022, is one of 52 in phase 2, and was the 204th registered.

Diabetic Retinopathy

779 studies on the registry are indexed under Diabetic Retinopathy; 143 are open to participants now.

Browse Diabetic Retinopathy studies →

Open to participants now

36 of the 267 studies in Diabetic Retinopathy with a site in United States are open now. Recruiting first, the newest first:

31 more — sign in →

All 36 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 92 Diabetic Retinopathy studies recruiting now, 60 (65%) set no upper age limit and 10 (11%) stop at 75 or younger; 8 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 267 studies in Diabetic Retinopathy with a site in United States, or all of them as a file.
02

Study summary

A prospective, randomized, double-masked study that evaluated the ocular efficacy and safety of two doses of the EYP-1901 intravitreal (IVT) insert compared to sham.

Read the detailed description

This study evaluated the ocular efficacy and safety of two doses of the EYP-1901 IVT insert compared to sham using a randomized double-masked trial design.

03

Conditions studied

  • Nonproliferative Diabetic Retinopathy

Browse trials for

Keywords

  • NPDR
  • EYP-1901
  • EyePoint
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have a \<=12%
  • Study eye with moderately severe to severe Non proliferative Diabetic Retinopathy (NPDR) (based on the Diabetic Retinopathy Severity Scale (DRSS) levels 47 or 53)
  • Best corrected visual acuity (BCVA) using Early Treatment Diabetic Retinopathy Study (ETDRS) letter score in the study eye of >=69 letters (approximate Snellen equivalent of 20/40 or better).

Exclusion criteria

Exclusion Criteria:

  • Presence of any active Center involved-diabetic macular edema in the study eye as determined by the Investigator on clinical examination, or within the central subfield thickness (CST) of the study eye, with a CST threshold greater than 320 microns.
  • Any evidence or documented history of prior focal or grid laser photocoagulation or any pan-retinal photocoagulation (PRP) in the study eye in the last 12 months.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
77 participants (actual)

Study arms

  • Experimental
    EYP-1901 2060 ug

    EYP-1901 2060 ug; single injection

    Drug: EYP-1901

  • Experimental
    EYP-1901 3090 ug

    EYP-1901 3090 ug; single injection

    Drug: EYP-1901

  • Sham comparator
    Sham IVT

    Sham IVT; single injection

    Other: Sham IVT

Interventions

  • EYP-1901 will be administered to the study eye by a single injection through the pars plana using a pre-loaded applicator with a 22-gauge needle. Each EYP-1901 IVT insert has been designed to deliver vorolanib into the vitreous humor for approximately 6 to 9 months.

    Also known as: Vorolanib

  • OtherSham IVT

    Sham injections will be used to maintain masking of investigational EYP-1901 therapy for study subjects.

06

What researchers measure

Primary outcomes

  1. Percentage of Subjects Improved >=2 Steps From Baseline in the DRSS Score at Week 36

    The DRSS used to describe overall retinopathy severity as well as the change in severity over time in the study eye. Severity ranges from level 10 (diabetic retinopathy absent) to level 85 (advanced proliferative diabetic retinopathy (PDR): posterior fundus obscured, or center of macula detached). Here, DRSS describes severity level 47 (moderately severe NPDR) and level 53 (severe NPDR) at Week 36 from baseline.

    Time frame: Baseline (Day 1) and Week 36

Secondary outcomes

  1. Percentage of Subjects Improved >=2 Steps From Baseline in the DRSS Score at Week 24 and Week 48

    The DRSS used to describe overall retinopathy severity as well as the change in severity over time in the study eye. Severity ranges from level 10 (diabetic retinopathy absent) to level 85 (advanced proliferative diabetic retinopathy (PDR): posterior fundus obscured, or center of macula detached). Here, DRSS describes severity levels 47 (moderately severe NPDR) and 53 (severe NPDR) at Weeks 24 and 48 from baseline.

    Time frame: Baseline (Day 1), Week 24, and Week 48

  2. Percentage of Subjects Improved >=2 Steps and >=3 Steps From Baseline in DRSS Score at Weeks 24, 36 and 48

    The DRSS used to describe overall retinopathy severity as well as the change in severity over time in the study eye. Severity ranges from level 10 (diabetic retinopathy absent) to level 85 (advanced PDR: posterior fundus obscured, or center of macula detached). Here, DRSS describes severity level 47 (moderately severe NPDR) and level 53 (severe NPDR) at Weeks 24, 36 and 48 from baseline.

    Time frame: Baseline (Day 1) and Weeks 24, 36 and 48

  3. Percentage of Subjects Worsened >=2 Steps and >=3 Steps From Baseline in DRSS Score at Weeks 24, 36 and 48

    The DRSS used to describe overall retinopathy severity as well as the change in severity over time in the study eye. Severity ranges from level 10 (diabetic retinopathy absent) to level 85 (advanced PDR: posterior fundus obscured, or center of macula detached). Here, DRSS describes severity level 47 (moderately severe NPDR) and level 53 (severe NPDR) at Weeks 24, 36 and 48 from baseline.

    Time frame: Baseline (Day 1) and Weeks 24, 36 and 48

  4. Percentage of Subjects Who Developed a Vision-Threatening Complication Due to Diabetic Retinopathy at Weeks 24, 36 and 48

    The vision threatening complications in the study eye due to diabetic retinopathy were indicated by the presence of "Vitreous hemorrhage" or the presence of "Tractional retinal detachment" reported on the Ocular Examination - Dilated Ophthalmoscopy CRF (PDR events), and "Neovascularization for the Iris" answered as "Yes" or "Neovascularization for the Angle" answered as "Yes" per the Ocular Examination - Slit Lamp Biomicroscopy CRF (anterior segment neovascularization (ASNV) events).

    Time frame: Weeks 24, 36 and 48

  5. Percentage of Subjects Who Developed Center Involved-Diabetic Macular Edema (CI-DME) at Weeks 24, 36 and 48

    The CI-DME in the study eye occurred when a treatment emergent adverse event (TEAE) with a mapped preferred term of 'Cystoid macular oedema', 'Diabetic retinal oedema', or 'Macular oedema' occurred in the study eye, in combination with the temporally closest centrally read custom algorithm CST measurement being greater than or equal to 320 microns.

    Time frame: Weeks 24, 36 and 48

  6. Time to Develop Any Neovascular Vision Threatening Complication (PDR/ASNV) at Weeks 24, 36 and 48

    Time to develop any PDR/ASNV was computed as the date of the first development of PDR/ASNV in the study eye minus the date of study treatment administration plus 1 day, divided by 7 days per week.

    Time frame: Weeks 24, 36 and 48

  7. Time to Develop CI-DME Through Weeks 24, 36 and 48

    The occurrence of a CI-DME event in the study eye was identified via examination of centrally read custom algorithm CST data and adverse events.

    Time frame: Weeks 24, 36 and 48

  8. Percentage of Subjects Who Received Anti-Vascular Endothelial Growth Factor (VEGF) or Additional Standard of Care Intervention Due to Ocular Diabetic Complications at Weeks 24, 36 and 48

    Percentage of subjects who received anti-VEGF or additional standard of care intervention due to ocular diabetic complications in the study eye are reported. Anti-VEGF use was identified in reported concomitant medication data.

    Time frame: Weeks 24, 36 and 48

  9. Percentage of Subjects Who Received PRP at Weeks 24, 36 and 48

    Percentage of subjects who received PRP in the study eye, inclusive of subjects undergoing vitrectomy with endo-laser are reported.

    Time frame: Weeks 24, 36 and 48

  10. Area Under the Curve (AUC) for Change From Baseline in BCVA at Weeks 24, 36 and 48

    The AUC for change from baseline in BCVA in the study eye were summarized. The AUC through each time point of interest was computed using the trapezoidal rule normalized to months, with a final unit of letters.

    Time frame: Weeks 24, 36 and 48

  11. Plasma Concentration of EYP-1901 and X-297 at Weeks 24, 36 and 48

    Blood samples were collected at the specific visits for the Pharmacokinetic (PK) analysis of EYP-1901 and its main metabolite concentrations.

    Time frame: Weeks 24, 36 and 48

  12. Number of Subjects With Ocular and Non-Ocular TEAEs and Serious TEAEs up to Week 48

    An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a patient or clinical investigation subject administered an investigational or marketed (medicinal) product and that does not necessarily have a causal relationship with the product. A serious AE is any AE that results in one of the following outcomes: death; life-threatening; requires in-patient hospitalization; results in a persistent or significant disability/incapacity; congenital anomaly/birth defect; other important medical event. The TEAEs are AEs that occur after the first dose of study treatment administration.

    Time frame: TEAEs were collected from the study drug administration (Day 1) up to end of the study, approximately 48 weeks.

07

Results

Posted Jul 28, 2025

Participant flow

This Phase 2 prospective, randomized, double-masked study was conducted in adult subjects with NPDR at 25 sites in the United States between 28 September 2022 and 06 May 2024.

Participant flow — Overall Study
MilestoneSham InjectionEYP-1901 2060 mcgEYP-1901 3090 mcg
Started262625
Completed212320
Not completed535
Withdrew: Adverse event: non-ocular010
Withdrew: Lost to follow-up214
Withdrew: Withdrawal by subject201
Withdrew: Death100
Withdrew: Other010

Outcome measures

PrimaryPercentage of Subjects Improved >=2 Steps From Baseline in the DRSS Score at Week 36

The DRSS used to describe overall retinopathy severity as well as the change in severity over time in the study eye. Severity ranges from level 10 (diabetic retinopathy absent) to level 85 (advanced proliferative diabetic retinopathy (PDR): posterior fundus obscured, or center of macula detached). Here, DRSS describes severity level 47 (moderately severe NPDR) and level 53 (severe NPDR) at Week 36 from baseline.

Time frame:
Baseline (Day 1) and Week 36
Reported as:
Number · percentage of subjects
Percentage of Subjects Improved >=2 Steps From Baseline in the DRSS Score at Week 36
percentage of subjectsSham InjectionEYP-1901 2060 mcgEYP-1901 3090 mcg
Percentage of Subjects Improved >=2 Steps From Baseline in the DRSS Score at Week 365.0 (0.1 to 24.9)0 (0.0 to 16.8)4.8 (0.1 to 23.8)
Statistical analysis
  • Sham Injection vs EYP-1901 2060 mcg · Difference in response percentage: -5.0 · 95% CI -24.9 to 13.4
  • Sham Injection vs EYP-1901 3090 mcg · Slope: -0.2 · 95% CI -20.6 to 20.6
SecondaryPercentage of Subjects Improved >=2 Steps From Baseline in the DRSS Score at Week 24 and Week 48

The DRSS used to describe overall retinopathy severity as well as the change in severity over time in the study eye. Severity ranges from level 10 (diabetic retinopathy absent) to level 85 (advanced proliferative diabetic retinopathy (PDR): posterior fundus obscured, or center of macula detached). Here, DRSS describes severity levels 47 (moderately severe NPDR) and 53 (severe NPDR) at Weeks 24 and 48 from baseline.

Time frame:
Baseline (Day 1), Week 24, and Week 48
Reported as:
Number · percentage of subjects
Percentage of Subjects Improved >=2 Steps From Baseline in the DRSS Score at Week 24 and Week 48
percentage of subjectsSham Injection (Week 24)Sham Injection (Week 48)EYP-1901 2060 mcg (Week 24)EYP-1901 2060 mcg (Week 48)EYP-1901 3090 mcg (Week 24)EYP-1901 3090 mcg (Week 48)
Percentage of Subjects Improved >=2 Steps From Baseline in the DRSS Score at Week 24 and Week 480 (0.0 to 18.5)0 (0.0 to 17.6)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 17.6)5.3 (0.1 to 26.0)
Statistical analysis
  • EYP-1901 3090 mcg (Week 48) · Difference in response percentage: 5.3 · 95% CI -13.2 to 26.0
SecondaryPercentage of Subjects Improved >=2 Steps and >=3 Steps From Baseline in DRSS Score at Weeks 24, 36 and 48

The DRSS used to describe overall retinopathy severity as well as the change in severity over time in the study eye. Severity ranges from level 10 (diabetic retinopathy absent) to level 85 (advanced PDR: posterior fundus obscured, or center of macula detached). Here, DRSS describes severity level 47 (moderately severe NPDR) and level 53 (severe NPDR) at Weeks 24, 36 and 48 from baseline.

Time frame:
Baseline (Day 1) and Weeks 24, 36 and 48
Reported as:
Number · percentage of subjects
Percentage of Subjects Improved >=2 Steps and >=3 Steps From Baseline in DRSS Score at Weeks 24, 36 and 48
percentage of subjectsSham InjectionEYP-1901 2060 mcgEYP-1901 3090 mcg
>=2-step improvement in DRSS: Week 240 (0.0 to 18.5)0 (0.0 to 20.6)0 (0.0 to 17.6)
>=2-step improvement in DRSS: Week 365.0 (0.1 to 24.9)0 (0.0 to 16.8)4.8 (0.1 to 23.8)
>=2-step improvement in DRSS: Week 480 (0.0 to 17.6)0 (0.0 to 16.8)5.3 (0.1 to 26.0)
>=3-step improvement in DRSS: Week 240 (0.0 to 18.5)0 (0.0 to 20.6)0 (0.0 to 17.6)
>=3-step improvement in DRSS: Week 360 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.1)
>=3-step improvement in DRSS: Week 480 (0.0 to 17.6)0 (0.0 to 16.8)0 (0.0 to 17.6)
SecondaryPercentage of Subjects Worsened >=2 Steps and >=3 Steps From Baseline in DRSS Score at Weeks 24, 36 and 48

The DRSS used to describe overall retinopathy severity as well as the change in severity over time in the study eye. Severity ranges from level 10 (diabetic retinopathy absent) to level 85 (advanced PDR: posterior fundus obscured, or center of macula detached). Here, DRSS describes severity level 47 (moderately severe NPDR) and level 53 (severe NPDR) at Weeks 24, 36 and 48 from baseline.

Time frame:
Baseline (Day 1) and Weeks 24, 36 and 48
Reported as:
Number · percentage of subjects
Percentage of Subjects Worsened >=2 Steps and >=3 Steps From Baseline in DRSS Score at Weeks 24, 36 and 48
percentage of subjectsSham InjectionEYP-1901 2060 mcgEYP-1901 3090 mcg
>=2-step worsening in DRSS: Week 240 (0.0 to 18.5)6.3 (0.2 to 30.2)0 (0.0 to 17.6)
>=2-step worsening in DRSS: Week 3610.0 (1.2 to 31.7)5.0 (0.1 to 24.9)0 (0.0 to 16.1)
>=2-step worsening in DRSS: Week 480 (0.0 to 17.6)5.0 (0.1 to 24.9)0 (0.0 to 17.6)
>=3-step worsening in DRSS: Week 240 (0.0 to 18.5)0 (0.0 to 20.6)0 (0.0 to 17.6)
>=3-step worsening in DRSS: Week 365.0 (0.1 to 24.9)0 (0.0 to 16.8)0 (0.0 to 16.1)
>=3-step worsening in DRSS: Week 480 (0.0 to 17.6)0 (0.0 to 16.8)0 (0.0 to 17.6)
SecondaryPercentage of Subjects Who Developed a Vision-Threatening Complication Due to Diabetic Retinopathy at Weeks 24, 36 and 48

The vision threatening complications in the study eye due to diabetic retinopathy were indicated by the presence of "Vitreous hemorrhage" or the presence of "Tractional retinal detachment" reported on the Ocular Examination - Dilated Ophthalmoscopy CRF (PDR events), and "Neovascularization for the Iris" answered as "Yes" or "Neovascularization for the Angle" answered as "Yes" per the Ocular Examination - Slit Lamp Biomicroscopy CRF (anterior segment neovascularization (ASNV) events).

Time frame:
Weeks 24, 36 and 48
Reported as:
Number · percentage of subjects
Percentage of Subjects Who Developed a Vision-Threatening Complication Due to Diabetic Retinopathy at Weeks 24, 36 and 48
percentage of subjectsSham InjectionEYP-1901 2060 mcgEYP-1901 3090 mcg
Week 240 (0.0 to 13.2)3.8 (0.1 to 19.6)0 (0.0 to 13.7)
Week 363.8 (0.1 to 19.6)3.8 (0.1 to 19.6)0 (0.0 to 13.7)
Week 483.8 (0.1 to 19.6)3.8 (0.1 to 19.6)0 (0.0 to 13.7)
SecondaryPercentage of Subjects Who Developed Center Involved-Diabetic Macular Edema (CI-DME) at Weeks 24, 36 and 48

The CI-DME in the study eye occurred when a treatment emergent adverse event (TEAE) with a mapped preferred term of 'Cystoid macular oedema', 'Diabetic retinal oedema', or 'Macular oedema' occurred in the study eye, in combination with the temporally closest centrally read custom algorithm CST measurement being greater than or equal to 320 microns.

Time frame:
Weeks 24, 36 and 48
Reported as:
Number · percentage of subjects
Percentage of Subjects Who Developed Center Involved-Diabetic Macular Edema (CI-DME) at Weeks 24, 36 and 48
percentage of subjectsSham InjectionEYP-1901 2060 mcgEYP-1901 3090 mcg
Week 240 (0.0 to 13.2)0 (0.0 to 13.2)0 (0.0 to 13.7)
Week 360 (0.0 to 13.2)0 (0.0 to 13.2)4.0 (0.1 to 20.4)
Week 483.8 (0.1 to 19.6)0 (0.0 to 13.2)8.0 (1.0 to 26.0)
SecondaryTime to Develop Any Neovascular Vision Threatening Complication (PDR/ASNV) at Weeks 24, 36 and 48

Time to develop any PDR/ASNV was computed as the date of the first development of PDR/ASNV in the study eye minus the date of study treatment administration plus 1 day, divided by 7 days per week.

Time frame:
Weeks 24, 36 and 48
Reported as:
Median · weeks
Time to Develop Any Neovascular Vision Threatening Complication (PDR/ASNV) at Weeks 24, 36 and 48
weeksSham InjectionEYP-1901 2060 mcgEYP-1901 3090 mcg
Week 24—NA (NA to NA)—
Week 36NA (NA to NA)NA (NA to NA)—
Week 48NA (NA to NA)NA (NA to NA)—
SecondaryTime to Develop CI-DME Through Weeks 24, 36 and 48

The occurrence of a CI-DME event in the study eye was identified via examination of centrally read custom algorithm CST data and adverse events.

Time frame:
Weeks 24, 36 and 48
Reported as:
Median · weeks
Time to Develop CI-DME Through Weeks 24, 36 and 48
weeksSham InjectionEYP-1901 2060 mcgEYP-1901 3090 mcg
Week 36——NA (NA to NA)
Week 48NA (NA to NA)—NA (NA to NA)
SecondaryPercentage of Subjects Who Received Anti-Vascular Endothelial Growth Factor (VEGF) or Additional Standard of Care Intervention Due to Ocular Diabetic Complications at Weeks 24, 36 and 48

Percentage of subjects who received anti-VEGF or additional standard of care intervention due to ocular diabetic complications in the study eye are reported. Anti-VEGF use was identified in reported concomitant medication data.

Time frame:
Weeks 24, 36 and 48
Reported as:
Number · percentage of subjects
Percentage of Subjects Who Received Anti-Vascular Endothelial Growth Factor (VEGF) or Additional Standard of Care Intervention Due to Ocular Diabetic Complications at Weeks 24, 36 and 48
percentage of subjectsSham InjectionEYP-1901 2060 mcgEYP-1901 3090 mcg
Week 247.7 (0.9 to 25.1)7.7 (0.9 to 25.1)4.0 (0.1 to 20.4)
Week 367.7 (0.9 to 25.1)7.7 (0.9 to 25.1)8.0 (1.0 to 26.0)
Week 487.7 (0.9 to 25.1)7.7 (0.9 to 25.1)12.0 (2.5 to 31.2)
SecondaryPercentage of Subjects Who Received PRP at Weeks 24, 36 and 48

Percentage of subjects who received PRP in the study eye, inclusive of subjects undergoing vitrectomy with endo-laser are reported.

Time frame:
Weeks 24, 36 and 48
Reported as:
Number · percentage of subjects
Percentage of Subjects Who Received PRP at Weeks 24, 36 and 48
percentage of subjectsSham InjectionEYP-1901 2060 mcgEYP-1901 3090 mcg
Week 240 (0.0 to 13.2)3.8 (0.1 to 19.6)0 (0.0 to 13.7)
Week 360 (0.0 to 13.2)3.8 (0.1 to 19.6)0 (0.0 to 13.7)
Week 480 (0.0 to 13.2)3.8 (0.1 to 19.6)0 (0.0 to 13.7)
SecondaryArea Under the Curve (AUC) for Change From Baseline in BCVA at Weeks 24, 36 and 48

The AUC for change from baseline in BCVA in the study eye were summarized. The AUC through each time point of interest was computed using the trapezoidal rule normalized to months, with a final unit of letters.

Time frame:
Weeks 24, 36 and 48
Reported as:
Mean · letters
Area Under the Curve (AUC) for Change From Baseline in BCVA at Weeks 24, 36 and 48
lettersSham InjectionEYP-1901 2060 mcgEYP-1901 3090 mcg
Week 24-0.32 ± 2.969-1.58 ± 8.4110.46 ± 4.070
Week 36-0.23 ± 3.234-1.52 ± 6.8190.03 ± 4.562
Week 48-0.38 ± 3.127-1.44 ± 6.369-0.02 ± 5.311
SecondaryPlasma Concentration of EYP-1901 and X-297 at Weeks 24, 36 and 48

Blood samples were collected at the specific visits for the Pharmacokinetic (PK) analysis of EYP-1901 and its main metabolite concentrations.

Time frame:
Weeks 24, 36 and 48
Reported as:
Mean · mcg/mL
Plasma Concentration of EYP-1901 and X-297 at Weeks 24, 36 and 48
mcg/mLEYP-1901 2060 mcgEYP-1901 3090 mcg
EYP-1901: Week 2411.852 ± 5.618014.064 ± 5.0654
EYP-1901: Week 367.660 ± 4.81879.708 ± 5.5782
EYP-1901: Week 486.698 ± 3.76428.194 ± 3.5894
X-297: Week 240.000 ± 0.00000.000 ± 0.0000
X-297: Week 360.999 ± 4.79170.275 ± 1.2877
X-297: Week 480.000 ± 0.00000.657 ± 2.8631
SecondaryNumber of Subjects With Ocular and Non-Ocular TEAEs and Serious TEAEs up to Week 48

An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a patient or clinical investigation subject administered an investigational or marketed (medicinal) product and that does not necessarily have a causal relationship with the product. A serious AE is any AE that results in one of the following outcomes: death; life-threatening; requires in-patient hospitalization; results in a persistent or significant disability/incapacity; congenital anomaly/birth defect; other important medical event. The TEAEs are AEs that occur after the first dose of study treatment administration.

Time frame:
TEAEs were collected from the study drug administration (Day 1) up to end of the study, approximately 48 weeks.
Reported as:
Count of participants · Participants
Number of Subjects With Ocular and Non-Ocular TEAEs and Serious TEAEs up to Week 48
ParticipantsSham Injection - Study EyeSham Injection - Non-study EyeSham Injection - Non-ocularEYP-1901 2060 mcg - Study EyeEYP-1901 2060 mcg - Non-study EyeEYP-1901 2060 mcg - Non-ocularEYP-1901 3090 mcg - Study EyeEYP-1901 3090 mcg - Non-study EyeEYP-1901 3090 mcg - Non-ocular
Any TEAE7915781611712
Any Serious TEAE112117001

Adverse events

Collected over TEAEs were collected from the study drug administration (Day 1) up to end of the study, approximately 48 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sham Injection - Study Eye0/26 (0%)1/26 (3.8%)7/26 (26.9%)
Sham Injection - Non-study Eye0/26 (0%)1/26 (3.8%)5/26 (19.2%)
Sham Injection - Non-ocular1/26 (3.8%)2/26 (7.7%)9/26 (34.6%)
EYP-1901 2060 mcg - Study Eye0/26 (0%)1/26 (3.8%)8/26 (30.8%)
EYP-1901 2060 mcg - Non-study Eye0/26 (0%)1/26 (3.8%)8/26 (30.8%)
EYP-1901 2060 mcg - Non-ocular1/26 (3.8%)7/26 (26.9%)14/26 (53.8%)
EYP-1901 3090 mcg - Study Eye0/25 (0%)0/25 (0%)8/25 (32%)
EYP-1901 3090 mcg - Non-study Eye0/25 (0%)0/25 (0%)5/25 (20%)
EYP-1901 3090 mcg - Non-ocular0/25 (0%)1/25 (4%)7/25 (28%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventSham Injection - Study EyeSham Injection - Non-study EyeSham Injection - Non-ocularEYP-1901 2060 mcg - Study EyeEYP-1901 2060 mcg - Non-study EyeEYP-1901 2060 mcg - Non-ocularEYP-1901 3090 mcg - Study EyeEYP-1901 3090 mcg - Non-study EyeEYP-1901 3090 mcg - Non-ocular
SepsisInfections and infestations0/260/260/260/260/262/260/250/250/25
Cardiac failure congestiveCardiac disorders0/260/260/260/260/260/260/250/251/25
Urinary tract infectionInfections and infestations0/260/260/260/260/260/260/250/251/25
Diabetic retinopathyEye disorders1/260/260/260/260/260/260/250/250/25
Macular oedemaEye disorders0/260/260/260/261/260/260/250/250/25
Vitreous haemorrhageEye disorders0/260/260/261/260/260/260/250/250/25
DeathGeneral disorders0/260/260/260/260/261/260/250/250/25
Oedema peripheralGeneral disorders0/260/260/260/260/261/260/250/250/25
CellulitisInfections and infestations0/260/260/260/260/261/260/250/250/25
EndophthalmitisInfections and infestations0/261/260/260/260/260/260/250/250/25
Most frequent other events
Showing 10 of 15
Most frequent other events
EventSham Injection - Study EyeSham Injection - Non-study EyeSham Injection - Non-ocularEYP-1901 2060 mcg - Study EyeEYP-1901 2060 mcg - Non-study EyeEYP-1901 2060 mcg - Non-ocularEYP-1901 3090 mcg - Study EyeEYP-1901 3090 mcg - Non-study EyeEYP-1901 3090 mcg - Non-ocular
Diabetic retinal oedemaEye disorders4/260/260/262/260/260/262/250/250/25
Diabetes mellitusMetabolism and nutrition disorders0/260/264/260/260/261/260/250/252/25
Diabetic retinopathyEye disorders1/262/260/263/263/260/260/253/250/25
Macular oedemaEye disorders0/262/260/261/263/260/261/251/250/25
Glucose urine presentInvestigations0/260/260/260/260/263/260/250/252/25
Eye painEye disorders0/261/260/260/260/260/262/251/250/25
Vitreous floatersEye disorders0/260/260/260/260/260/262/250/250/25
Conjunctival haemorrhageEye disorders0/260/260/262/260/260/261/250/250/25
Visual acuity reducedEye disorders2/260/260/260/262/260/260/250/250/25
InfluenzaInfections and infestations0/260/262/260/260/260/260/250/250/25

Baseline characteristics

Full Analysis Set (FAS) included all subjects who received at least 1 dose of study treatment (EYP-1901 or sham).

Age, Continuous
Age, Continuous(years)Sham InjectionEYP-1901 2060 mcgEYP-1901 3090 mcgTotal
Mean56.9 ± 11.9556.8 ± 11.7960.2 ± 9.9857.9 ± 11.26
Sex: Female, Male
Sex: Female, Male(Participants)Sham InjectionEYP-1901 2060 mcgEYP-1901 3090 mcgTotal
Female1312934
Male13141643
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Sham InjectionEYP-1901 2060 mcgEYP-1901 3090 mcgTotal
Hispanic or Latino98825
Not Hispanic or Latino17161750
Unknown or Not Reported0202
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Sham InjectionEYP-1901 2060 mcgEYP-1901 3090 mcgTotal
Asian2114
Black1359
White21191858
American Indian or Alaskan Native0202
Other2114
08

Study locations

36 sites
  • EyePoint Investigative Site
    Phoenix, Arizona 85020, United States
  • EyePoint Investigative Site
    Huntington Beach, California 92647, United States
  • EyePoint Investigative Site
    Oxnard, California 93036, United States
  • EyePoint Investigative Site
    Palm Desert, California 92211, United States
  • EyePoint Investigative Site
    Pasadena, California 90041, United States
  • EyePoint Investigative Site
    Poway, California 92064, United States
  • EyePoint Investigative Site
    Sacramento, California 95825, United States
  • EyePoint Investigative Site
    Danbury, Connecticut 06810, United States
  • EyePoint Investigative Site
    Clearwater, Florida 33761, United States
  • EyePoint Investigative Site
    Melbourne, Florida 32901, United States
  • EyePoint Investigative Site
    Miami, Florida 33143, United States
  • EyePoint Investigative Site
    Winter Haven, Florida 33880, United States
  • EyePoint Investigative Site
    Lemont, Illinois 60439, United States
  • EyePoint Investigative Site
    Indianapolis, Indiana 46290, United States
  • EyePoint Investigative Site
    Lenexa, Kansas 66215, United States
  • EyePoint Investigative Site
    Baltimore, Maryland 21209, United States
  • EyePoint Investigative Site
    Hagerstown, Maryland 21740, United States
  • EyePoint Investigative Site
    Springfield, Massachusetts 01107, United States
  • EyePoint Investigative Site
    Reno, Nevada 89502, United States
  • EyePoint Investigative Site
    Bloomfield, New Jersey 07003, United States
  • EyePoint Investigative Site
    Toms River, New Jersey 08755, United States
  • EyePoint Investigative Site
    Great Neck, New York 11021, United States
  • EyePoint Investigative Site
    Erie, Pennsylvania 16501, United States
  • EyePoint Investigative Site
    Florence, South Carolina 29501, United States
  • EyePoint Investigative Site
    Ladson, South Carolina 29456, United States
  • EyePoint Investigative Site
    Rapid City, South Dakota 57701, United States
  • EyePoint Investigative Site
    Germantown, Tennessee 38138, United States
  • EyePoint Investigative Site
    Abilene, Texas 79606, United States
  • EyePoint Investigative Site
    Austin, Texas 78705, United States
  • EyePoint Investigative Site
    Houston, Texas 78240, United States
  • EyePoint Investigative Site
    McAllen, Texas 78503, United States
  • EyePoint Investigative Site
    Plano, Texas 75075, United States
  • EyePoint Investigative Site
    San Antonio, Texas 78247, United States
  • EyePoint Investigative Site
    The Woodlands, Texas 77384, United States
  • EyePoint Investigative Site
    Lynchburg, Virginia 24502, United States
  • EyePoint Investigative Site
    Bellevue, Washington 98004, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2022 to primary completion in Feb 2024, 16 months.

Results were first posted in Jul 2025, 1 year 5 months after primary completion.

Of 30 industry-sponsored phase 2 interventional studies under Diabetic Retinopathy, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 37. This study's 16 months is below that.

Counting every sponsor, half of 43 studies reached it within 31 months; a quarter within 17 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2022
First posted
May 20, 2022
StartActual
Sep 28, 2022
Primary completionActual
Feb 12, 2024
CompletionActual
May 6, 2024
Results first posted
Jul 28, 2025
Last update
Aug 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05383209
Lead sponsor
EyePoint Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
May 20, 2022
Start date
Sep 28, 2022
Primary completion
Feb 12, 2024
Completion
May 6, 2024
Results posted
Jul 28, 2025
Last update
Aug 15, 2025

Study contacts

Ramiro Ribeiro, MD, PhD
study director · EyePoint Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vorolanib

Start the discussion